REYKJAVIK, Iceland -- 13 Nov, 2024 -- Akthelia Pharmaceuticals is featured in today's edition of the leading Icelandic business newspaper Viðskiptablaðið.
The article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring both for oncology and inflammatory bowel disorders, as it targets mucositis/mucosal barrier injury. MBI has emerged as the common pathology underlying infection and sepsis risk that presents as febrile neutropenia, the leading dose-limiting complication and cause of treatment-related mortality in cancer treatment, HSCT and GVHD.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals is a pioneering biopharmaceutical company, focusing on therapeutics that target mucosal barrier injury and epithelial integrity, via a novel biology-driven immunotherapeutic strategy that upregulates epithelial surfaces.
Akthelia's lead program is a late preclinical stage asset with potential to be a first-in-class oral therapeutic addressing the large unmet need to improve cancer care outcomes by reducing the risk of chemotherapy-induced bloodstream infections. Akthelia's platform also addresses the urgent global threat of antibiotic bacterial resistance (AMR).
CONTACTS
Egill Masson CEO egill.masson@aktheliapharma.com
Akthelia Pharmaceuticals Grandagardi 16 101 Reykjavik Iceland